

Insulin Abasaglar (insulin glargine) 100 units per ml

Recommendation

Insulin Abasaglar is the preferred formulation of insulin glargine 100 units per ml for patients newly commenced on insulin glargine 100 units per ml.

Insulin glargine 100 units per ml should be prescribed by brand name and patients should be maintained on the same brand.

Patients currently receiving Lantus should remain on Lantus (prescribed by brand name)

Insulin Abasaglar is a biosimilar formulation of insulin glargine.

Insulin glargine biosimilar (Abasaglar) is licensed for the treatment of diabetes mellitus in adults, young people and children over 2 years.

Abasaglar is a basal insulin for once daily use and is bioequivalent to insulin glargine (Lantus).

Abasaglar is available as cartridges of 100 units/ml for use in the reusable pen or as a pre-filled pen 100 units/ml. The pen device is the Kwik pen.

NICE guidelines on management of type 1 diabetes recommend insulin detemir twice a day as the preferred basal therapy. Insulin glargine once a day is recommended as an alternative treatment.

NICE guidelines on management of type 2 diabetes recommend NPH insulin as the preferred basal therapy. Insulin glargine or insulin detemir are recommended alternatives in certain circumstances.

Abasaglar should be prescribed by brand name to avoid unintentional substitution for Lantus or Toujeo (300 unit preparation of insulin glargine).

Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)

Date: Feb 2016

Address: c/o Canterbury and Coastal CCG, Brook House, John Wilson Business Park, Whitstable, CT5 3DD

Contact: T: 01227 791267 | E: accg.eastkentprescribing@nhs.net